Clinical Trials Logo

Clinical Trial Summary

The Nucleus 24 Auditory Brainstem Implant (ABI) is the only FDA approved device for restoration of meaningful hearing in Neurofibromatosis Type 2 (NF2) patients. This device has been discontinued, meaning that there is no commercially approved device currently available. The replacement model, the ABI541 (an unapproved device), is being investigated in ongoing clinical trials. A compassionate use arm of a clinical trial allows patients with NF2 to be implanted with this new ABI.


Clinical Trial Description

Currently, the Nucleus 24 (ABI24M) Auditory Brainstem Implant (ABI) is approved for use in individuals 12 years of age or older who have been diagnosed with Neurofibromatosis Type 2 (NF2). Implantation may occur during first or second side tumor removal or in patients with previously removed vestibular schwannomas bilaterally. As the ABI24M is now obsolete, there is currently no commercially approved device available to restore useful hearing in patients. While the manufacturer of the device is pursuing commercial approval of the ABI541, it is anticipated that it may be several months or years before final approval. However, it is preferable to place the device at the time of tumor removal while the patient has an open craniotomy site, thereby avoiding a second surgery and its associated risks solely for the purpose device implantation. In addition, placement of an ABI at the time of tumor removal optimizes auditory rehabilitation, providing critical auditory sensations that may more effectively maintain auditory pathways. The FDA approved a compassionate use arm for an ongoing clinical trial to permit implantation of the ABI541 in up to 10 NF2 patients.

Patients will undergo pre-operative evaluation for ABI surgery. Those who are appropriate for surgery will undergo a procedure for implantation of the ABI541. As per manufacturer protocol, the parameters of the ABI541 including adjustment of electrode sensitivities and activation of specific electrodes will be completed at each follow-up visit post-operatively. This process involves adjustment of device parameters by a trained audiologist who subsequently administers audiologic tests to confirm optimal activation of the ABI541.

All audiologic testing and assessments represent the standard of care. These post-operative follow-up appointments will occur at 4-12 weeks, three, six, and twelve months, and biannually thereafter. Timing of these appointments may vary by as much as four weeks prior to or after the planned follow-up date (e.g. between 2-4 months for the 3 month follow-up). Unscheduled visits will be taken in the Otology clinic as needed to address any concerns patients may have regarding the use of their Nucleus ABI541. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02589912
Study type Expanded Access
Source Massachusetts Eye and Ear Infirmary
Contact
Status No longer available
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT05521048 - Doxycycline in Cutaneous Schwannoma (NF2) Phase 1/Phase 2
Completed NCT01207687 - Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Phase 2
Completed NCT01767792 - Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Completed NCT01880749 - Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas Early Phase 1
Recruiting NCT05130866 - Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas Phase 2/Phase 3
Recruiting NCT04374305 - Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Phase 2
Completed NCT01125046 - Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Phase 2
Completed NCT03210285 - WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Completed NCT02934256 - Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Terminated NCT01345136 - Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Phase 2
Completed NCT02104323 - Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Phase 2
Completed NCT02246231 - Effect of Implant Position on Magnetic Resonance Image Distortion N/A
Terminated NCT02282917 - Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma Early Phase 1
Completed NCT02129647 - Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Phase 2